**Contact**
Merck KGaA, Darmstadt, Germany
Investor Relations
Frankfurter Strasse 250
64293 Darmstadt
Germany
Phone: +49 6151 72 3321
e-mail: investor.relations@emdgroup.com
www.emdgroup.com

WKN: 659990
ISIN: DE0006599905
Ticker Symbol: MRK

# Financial Statements Q1 2019 – Q1 2020

**Content**

**1 Income statements**
1.1 Group, quarterly
1.2 Healthcare, quarterly
1.3 Life Science, quarterly
1.4 Performance Materials, quarterly
1.5 Corporate/Others, quarterly

**2 Cash flow statement**

**3 Balance sheet**

**EBITDA pre Merck KGaA, Darmstadt, Germany**

| € million | 2019 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | 2020 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Change YoY Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare | 332.0 | 527.8 | 859.8 | 500.8 | 1,360.6 | 561.1 | 1,061.9 | 1,921.7 | 472.1 | | | | | | | | 42.2% | | | | | | | |
| *in % of net sales* | *22.4%* | *31.5%* | *27.2%* | *28.5%* | *27.7%* | *31.2%* | *29.9%* | *28.6%* | *27.8%* | | | | | | | | | | | | | | | |
| Life Science | 515.7 | 533.3 | 1,049.0 | 531.1 | 1,580.1 | 548.7 | 1,079.8 | 2,128.9 | 552.7 | | | | | | | | 7.2% | | | | | | | |
| *in % of net sales* | *31.0%* | *31.3%* | *31.2%* | *31.0%* | *31.1%* | *30.8%* | *30.9%* | *31.0%* | *31.2%* | | | | | | | | | | | | | | | |
| Performance Materials | 192.6 | 190.3 | 382.9 | 177.5 | 560.4 | 243.0 | 420.5 | 803.4 | 285.5 | | | | | | | | 48.3% | | | | | | | |
| *in % of net sales* | *31.9%* | *32.3%* | *32.1%* | *30.5%* | *31.6%* | *30.5%* | *30.5%* | *31.2%* | *31.7%* | | | | | | | | | | | | | | | |
| Corporate/Others | -111.8 | -112.1 | -223.9 | -98.1 | -322.0 | -147.2 | -245.3 | -469.2 | -129.1 | | | | | | | | 15.5% | | | | | | | |
| **Group** | **928.5** | **1,139.3** | **2,067.8** | **1,111.3** | **3,179.1** | **1,205.7** | **2,316.9** | **4,384.8** | **1,181.3** | | | | | | | | 27.2% | | | | | | | |
| *in % of net sales* | *24.8%* | *28.7%* | *26.8%* | *27.4%* | *27.0%* | *27.5%* | *27.5%* | *27.1%* | *27.0%* | | | | | | | | | | | | | | | |

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**

| **Group** | 2019 | | | | | | | | 2020 | | | | | | | | Change YoY | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| € million | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| **Net sales** | **3,745.8** | **3,971.4** | **7,717.2** | **4,053.7** | **11,770.9** | **4,380.8** | **8,434.5** | **16,151.7** | **4,369.7** | | | | | | | | 16.7% | | | | | | | |
| Cost of sales | -1,383.5 | -1,454.4 | -2,838.0 | -1,477.9 | -4,315.9 | -1,690.4 | -3,168.3 | -6,006.3 | -1,653.5 | | | | | | | | 19.5% | | | | | | | |
| thereof amortization of intangible assets | -43.5 | -43.7 | -87.2 | -44.0 | -131.2 | -56.9 | -100.9 | -188.1 | -56.7 | | | | | | | | 30.5% | | | | | | | |
| Gross profit | 2,362.2 | 2,517.0 | 4,879.2 | 2,575.8 | 7,455.1 | 2,690.4 | 5,266.2 | 10,145.5 | 2,716.2 | | | | | | | | 15.0% | | | | | | | |
| *in % of net sales* | *63.1%* | *63.4%* | *63.2%* | *63.5%* | *63.3%* | *61.4%* | *62.4%* | *62.8%* | *62.2%* | | | | | | | | | | | | | | | |
| SG&A | -1,456.8 | -1,345.3 | -2,802.1 | -1,409.5 | -4,211.6 | -1,545.6 | -2,955.2 | -5,757.3 | -1,421.0 | | | | | | | | -2.5% | | | | | | | |
| *in % of net sales* | *38.9%* | *33.9%* | *36.3%* | *34.8%* | *35.8%* | *35.3%* | *35.0%* | *35.6%* | *32.5%* | | | | | | | | | | | | | | | |
| Marketing and selling expenses | -1,090.8 | -1,156.9 | -2,247.6 | -1,100.4 | -3,348.1 | -1,228.4 | -2,328.8 | -4,576.5 | -1,058.7 | | | | | | | | -2.9% | | | | | | | |
| thereof amortization of intangible assets (M&S) | -222.6 | -225.0 | -447.6 | -217.6 | -665.2 | -257.4 | -475.0 | -922.6 | -158.8 | | | | | | | | -28.7% | | | | | | | |
| Administration expenses | -283.0 | -269.1 | -552.1 | -267.5 | -819.6 | -334.3 | -601.8 | -1,153.9 | -288.5 | | | | | | | | 1.9% | | | | | | | |
| Impairment losses and reversals (IFRS 9) | -3.9 | 2.2 | -1.8 | -1.2 | -3.0 | -4.6 | -5.8 | -7.5 | 6.0 | | | | | | | | n.m. | | | | | | | |
| Other operating expenses/income | -79.1 | 78.5 | -0.6 | -40.4 | -40.9 | 21.6 | -18.8 | -19.3 | -79.8 | | | | | | | | 0.9% | | | | | | | |
| Impairments** | 0.0 | 0.0 | 0.0 | -8.4 | -8.4 | -0.7 | -9.1 | -9.1 | -1.9 | | | | | | | | >1.000% | | | | | | | |
| Research and development | -526.6 | -553.2 | -1,079.9 | -558.3 | -1,638.1 | -630.1 | -1,188.4 | -2,268.2 | -579.2 | | | | | | | | 10.0% | | | | | | | |
| *in % of net sales* | *14.1%* | *13.9%* | *14.0%* | *13.8%* | *13.9%* | *14.4%* | *14.1%* | *14.0%* | *13.3%* | | | | | | | | | | | | | | | |
| thereof amortization of intangible assets (R&D) | -1.0 | -0.7 | -1.6 | -1.9 | -3.5 | -5.1 | -7.0 | -8.6 | -2.3 | | | | | | | | 144.0% | | | | | | | |
| **EBIT** | **378.8** | **618.4** | **997.3** | **608.0** | **1,605.3** | **514.6** | **1,122.7** | **2,120.0** | **715.9** | | | | | | | | 89.0% | | | | | | | |
| *in % of net sales* | *10.1%* | *15.6%* | *12.9%* | *15.0%* | *13.6%* | *11.7%* | *13.3%* | *13.1%* | *16.4%* | | | | | | | | | | | | | | | |
| Depreciation and amortization | 474.0 | 455.4 | 929.4 | 464.3 | 1,393.7 | 552.6 | 1,016.9 | 1,946.3 | 431.5 | | | | | | | | -9.0% | | | | | | | |
| **EBITDA** | **852.8** | **1,073.9** | **1,926.7** | **1,072.3** | **2,999.0** | **1,067.3** | **2,139.6** | **4,066.3** | **1,147.5** | | | | | | | | 34.6% | | | | | | | |
| *in % of net sales* | *22.8%* | *27.0%* | *25.0%* | *26.5%* | *25.5%* | *24.4%* | *25.4%* | *25.2%* | *26.3%* | | | | | | | | | | | | | | | |
| **EBITDA pre** | **928.5** | **1,139.3** | **2,067.8** | **1,111.3** | **3,179.1** | **1,205.7** | **2,316.9** | **4,384.8** | **1,181.3** | | | | | | | | 27.2% | | | | | | | |
| *in % of net sales* | *24.8%* | *28.7%* | *26.8%* | *27.4%* | *27.0%* | *27.5%* | *27.5%* | *27.1%* | *27.0%* | | | | | | | | | | | | | | | |
| Financial result | -112.6 | -61.1 | -173.7 | -134.9 | -308.5 | -76.1 | -210.9 | -384.6 | -98.5 | | | | | | | | -12.5% | | | | | | | |
| Profit before income tax from continuing operations | 266.2 | 557.4 | 823.6 | 473.2 | 1,296.8 | 438.6 | 911.8 | 1,735.4 | 617.5 | | | | | | | | 131.9% | | | | | | | |
| Income tax | -67.2 | -136.2 | -203.4 | -133.7 | -337.1 | -102.6 | -236.4 | -439.8 | -159.4 | | | | | | | | 137.4% | | | | | | | |
| *Income tax rate* | *25.2%* | *24.4%* | *24.7%* | *28.3%* | *26.0%* | *23.4%* | *25.9%* | *25.3%* | *25.8%* | | | | | | | | | | | | | | | |
| Profit after tax from continuing operations | 199.1 | 421.1 | 620.2 | 339.5 | 959.7 | 335.9 | 675.4 | 1,295.6 | 458.0 | | | | | | | | 130.1% | | | | | | | |
| Profit after tax from discontinued operations | -9.6 | 49.7 | 40.2 | 2.4 | 42.6 | -14.7 | -12.2 | 27.9 | 0.0 | | | | | | | | -100.0% | | | | | | | |
| Profit after tax | 189.5 | 470.9 | 660.4 | 341.9 | 1,002.3 | 321.3 | 663.2 | 1,323.6 | 458.0 | | | | | | | | 141.7% | | | | | | | |
| **of which: attributable to Merck KGaA shareholders (n** | **188.6** | **470.9** | **659.5** | **342.7** | **1,002.2** | **318.1** | **660.8** | **1,320.2** | **456.1** | | | | | | | | 141.9% | | | | | | | |
| **of which: attributable to non-controlling interests** | **1.0** | **0.0** | **1.0** | **-0.8** | **0.1** | **3.2** | **2.4** | **3.3** | **1.9** | | | | | | | | 99.8% | | | | | | | |
| **EPS in €** | **0.43** | **1.08** | **1.52** | **0.79** | **2.31** | **0.73** | **1.52** | **3.04** | **1.05** | | | | | | | | 144.2% | | | | | | | |
| thereof from continuing operations | 0.45 | 0.97 | 1.42 | 0.78 | 2.20 | 0.77 | 1.55 | 2.97 | 1.05 | | | | | | | | 133.3% | | | | | | | |
| thereof from discontinued operations | -0.02 | 0.11 | 0.09 | 0.01 | 0.10 | -0.03 | -0.02 | 0.07 | 0.00 | | | | | | | | -100.0% | | | | | | | |
| **EPS pre in €*** | **1.13** | **1.54** | **2.67** | **1.35** | **4.02** | **1.54** | **2.89** | **5.56** | **1.50** | | | | | | | | 32.7% | | | | | | | |
| **Number of theoretical shares in million** | 434.8 | 434.8 | 434.8 | 434.8 | 434.8 | 434.8 | 434.8 | 434.8 | 434.8 | | | | | | | | | | | | | | | |
| **Reconciliation to EBITDA pre** | | | | | | | | | | | | | | | | | | | | | | | | |
| EBITDA | 852.8 | 1,073.9 | 1,926.7 | 1,072.3 | 2,999.0 | 1,067.3 | 2,139.6 | 4,066.3 | 1,147.5 | | | | | | | | 34.5% | | | | | | | |
| **Adjustments** | | | | | | | | | | | | | | | | | | | | | | | | |
| thereof: Cost of Sales | 16.0 | 3.4 | 19.4 | 7.3 | 26.7 | 29.4 | 36.7 | 56.1 | 20.2 | | | | | | | | 26.5% | | | | | | | |
| thereof: Marketing and selling expenses | 3.0 | 4.8 | 7.8 | 1.9 | 9.7 | 0.6 | 2.5 | 10.3 | 2.2 | | | | | | | | -26.2% | | | | | | | |
| thereof: Administration expenses | 36.7 | 10.6 | 47.4 | 21.9 | 69.3 | 39.8 | 61.7 | 109.0 | 16.4 | | | | | | | | -55.3% | | | | | | | |
| thereof: Other operating expenses/income | 4.3 | 29.5 | 33.8 | 17.6 | 51.4 | 62.8 | 80.4 | 114.2 | -3.7 | | | | | | | | n.m. | | | | | | | |
| thereof: Research and development | 15.7 | 17.1 | 32.8 | -9.7 | 23.1 | 5.8 | -3.9 | 28.9 | -1.2 | | | | | | | | n.m. | | | | | | | |
| **Total** | **75.7** | **65.4** | **141.1** | **39.0** | **180.1** | **138.4** | **177.3** | **318.5** | **33.8** | | | | | | | | -55.3% | | | | | | | |
| **EBITDA pre** | **928.5** | **1,139.3** | **2,067.8** | **1,111.3** | **3,179.1** | **1,205.7** | **2,316.9** | **4,384.8** | **1,181.3** | | | | | | | | 27.2% | | | | | | | |

Sum of items may not foot due to rounding.
* for continuing operations
** only reflects impairments which classified as adjustments

**Reconciliation to EBITDA, EBITDA pre and EPS pre**

| **Group** | 2019 | | | | | | | | 2020 | | | | | | | | Change YoY | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| € million | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| **a) Reconciliation to EBITDA and EBITDA pre** | | | | | | | | | | | | | | | | | | | | | | | | |
| **EBITDA** | | | | | | | | | | | | | | | | | | | | | | | | |
| EBIT | 378.8 | 618.4 | 997.3 | 608.0 | 1,605.3 | 514.6 | 1,122.7 | 2,120.0 | 715.9 | | | | | | | | 89.0% | | | | | | | |
| Depreciation and amortization | 474.0 | 455.4 | 929.4 | 464.3 | 1,393.7 | 552.6 | 1,016.9 | 1,946.3 | 431.5 | | | | | | | | -9.0% | | | | | | | |
| Regular depreciation and amortization* | 207.1 | 186.0 | 393.0 | 192.4 | 585.4 | 232.6 | 425.0 | 818.0 | 211.8 | | | | | | | | 2.3% | | | | | | | |
| Amortization of purchased intangible assets | 266.9 | 269.5 | 536.4 | 263.5 | 799.9 | 319.4 | 582.9 | 1,119.2 | 217.8 | | | | | | | | -18.4% | | | | | | | |
| Impairments** | 0.0 | 0.0 | 0.0 | 8.4 | 8.4 | 0.7 | 9.1 | 9.1 | 1.9 | | | | | | | | >1.000% | | | | | | | |
| **Total** | **852.8** | **1,073.9** | **1,926.7** | **1,072.3** | **2,999.0** | **1,067.3** | **2,139.6** | **4,066.3** | **1,147.4** | | | | | | | | 34.5% | | | | | | | |
| **Adjustments** | | | | | | | | | | | | | | | | | | | | | | | | |
| Acquisition costs | 0.2 | 0.2 | 0.4 | 0.1 | 0.4 | 83.4 | 83.4 | 83.8 | 19.0 | | | | | | | | >1.000% | | | | | | | |
| Restructuring costs | 61.3 | 39.1 | 100.4 | 10.5 | 110.8 | 9.6 | 20.0 | 120.4 | 15.5 | | | | | | | | -74.8% | | | | | | | |
| Integration costs/IT costs | 13.0 | 22.0 | 35.0 | 27.8 | 62.8 | 32.4 | 60.2 | 95.2 | 21.7 | | | | | | | | 67.0% | | | | | | | |
| Gain (-)/ losses (+) on the divestment of businesse | 1.8 | -1.7 | 0.1 | -3.7 | -3.6 | 9.5 | 5.8 | 5.9 | -30.0 | | | | | | | | n.m. | | | | | | | |
| Other one-time costs | -0.6 | 5.9 | 5.3 | 4.4 | 9.6 | 3.5 | 7.9 | 13.2 | 7.6 | | | | | | | | n.m. | | | | | | | |
| **Total** | **75.7** | **65.4** | **141.1** | **39.0** | **180.1** | **138.4** | **177.3** | **318.5** | **33.8** | | | | | | | | -55.3% | | | | | | | |
| **EBITDA pre** | **928.5** | **1,139.3** | **2,067.8** | **1,111.3** | **3,179.1** | **1,205.7** | **2,316.9** | **4,384.8** | **1,181.3** | | | | | | | | 27.2% | | | | | | | |
| **b) Reconciliation to EPS pre** | | | | | | | | | | | | | | | | | | | | | | | | |
| **1) Reconciliation starting from EBITDA pre** | | | | | | | | | | | | | | | | | | | | | | | | |
| EBITDA pre | 928.5 | 1,139.3 | 2,067.8 | 1,111.3 | 3,179.1 | 1,205.7 | 2,316.9 | 4,384.8 | 1,181.3 | | | | | | | | 27.2% | | | | | | | |
| Regular depreciation and amortization* | -207.1 | -186.0 | -393.0 | -192.4 | -585.4 | -232.6 | -425.0 | -818.0 | -211.8 | | | | | | | | 2.3% | | | | | | | |
| Financial result | -112.6 | -61.1 | -173.7 | -134.9 | -308.5 | -76.1 | -210.9 | -384.6 | -98.5 | | | | | | | | -12.5% | | | | | | | |
| Adjustments within Financial result | 45.1 | 0.0 | 45.1 | 0.0 | 45.1 | 0.0 | 0.0 | 45.1 | 0.0 | | | | | | | | | | | | | | | |
| Profit before income tax pre | 653.9 | 892.3 | 1,546.2 | 784.0 | 2,330.2 | 897.0 | 1,681.0 | 3,227.2 | 871.0 | | | | | | | | 33.2% | | | | | | | |
| Income tax pre | -163.5 | -223.1 | -386.5 | -196.0 | -582.6 | -224.2 | -420.3 | -806.8 | -217.8 | | | | | | | | 33.2% | | | | | | | |
| *underlying tax rate* | *25.0%* | *25.0%* | *25.0%* | *25.0%* | *25.0%* | *25.0%* | *25.0%* | *25.0%* | *25.0%* | | | | | | | | | | | | | | | |
| Non-controlling interest | -1.0 | 0.0 | -1.0 | 0.8 | -0.1 | -3.2 | -2.4 | -3.3 | -1.9 | | | | | | | | 99.8% | | | | | | | |
| Net income pre | 489.5 | 669.2 | 1,158.7 | 588.8 | 1,747.5 | 669.5 | 1,258.4 | 2,417.1 | 651.4 | | | | | | | | 33.1% | | | | | | | |
| **EPS pre in €*** ** | **1.13** | **1.54** | **2.67** | **1.35** | **4.02** | **1.54** | **2.89** | **5.56** | **1.50** | | | | | | | | 33.1% | | | | | | | |
| **2) Reconciliation starting from Profit before tax** | | | | | | | | | | | | | | | | | | | | | | | | |
| Profit before income tax | 266.2 | 557.4 | 823.6 | 473.2 | 1,296.8 | 438.6 | 911.8 | 1,735.4 | 617.5 | | | | | | | | 131.9% | | | | | | | |
| Amortization of purchased intangible assets | 266.9 | 269.5 | 536.4 | 263.5 | 799.9 | 319.4 | 582.9 | 1,119.2 | 217.8 | | | | | | | | -18.4% | | | | | | | |
| Impairments** | 0.0 | 0.0 | 0.0 | 8.4 | 8.4 | 0.7 | 9.1 | 9.1 | 1.9 | | | | | | | | >1.000% | | | | | | | |
| Adjustments | | | | | | | | | | | | | | | | | | | | | | | | |
| Acquisition costs | 0.2 | 0.2 | 0.4 | 0.1 | 0.4 | 83.4 | 83.4 | 83.8 | 19.0 | | | | | | | | >1.000% | | | | | | | |
| Restructuring costs | 61.3 | 39.1 | 100.4 | 10.5 | 110.8 | 9.6 | 20.0 | 120.4 | 15.5 | | | | | | | | -74.8% | | | | | | | |
| Integration costs/IT costs | 13.0 | 22.0 | 35.0 | 27.8 | 62.8 | 32.4 | 60.2 | 95.2 | 21.7 | | | | | | | | 67.0% | | | | | | | |
| Gain (-)/ losses (+) on the divestment of businesse | 1.8 | -1.7 | 0.1 | -3.7 | -3.6 | 9.5 | 5.8 | 5.9 | -30.0 | | | | | | | | n.m. | | | | | | | |
| Other one-time costs | -0.6 | 5.9 | 5.3 | 4.4 | 9.6 | 3.5 | 7.9 | 13.2 | 7.6 | | | | | | | | n.m. | | | | | | | |
| Adjustments within Financial result | 45.1 | 0.0 | 45.1 | 0.0 | 45.1 | 0.0 | 0.0 | 45.1 | 0.0 | | | | | | | | | | | | | | | |
| Total adjustments | 120.7 | 65.4 | 186.2 | 39.0 | 225.1 | 138.4 | 177.3 | 363.5 | 33.8 | | | | | | | | -72.0% | | | | | | | |
| Profit before income tax pre | 653.9 | 892.3 | 1,546.2 | 784.0 | 2,330.2 | 897.0 | 1,681.0 | 3,227.2 | 871.0 | | | | | | | | 33.2% | | | | | | | |
| Income tax pre | -163.5 | -223.1 | -386.5 | -196.0 | -582.6 | -224.2 | -420.3 | -806.8 | -217.7 | | | | | | | | 33.2% | | | | | | | |
| *underlying tax rate* | *25.0%* | *25.0%* | *25.0%* | *25.0%* | *25.0%* | *25.0%* | *25.0%* | *25.0%* | *25.0%* | | | | | | | | | | | | | | | |
| **Total costs excluded from Net income** | **300.9** | **198.3** | **499.2** | **246.1** | **745.4** | **351.5** | **597.6** | **1,096.8** | **195.2** | | | | | | | | -35.1% | | | | | | | |
| Total costs excluded from EPS in € | 0.69 | 0.46 | 1.15 | 0.57 | 1.71 | 0.81 | 1.37 | 2.52 | 0.45 | | | | | | | | -34.8% | | | | | | | |
| Non-controlling interest | -1.0 | 0.0 | -1.0 | 0.8 | -0.1 | -3.2 | -2.4 | -3.3 | -1.9 | | | | | | | | 99.8% | | | | | | | |
| Net income pre | 489.5 | 669.2 | 1,158.7 | 588.8 | 1,747.5 | 669.5 | 1,258.4 | 2,417.1 | 651.3 | | | | | | | | 33.1% | | | | | | | |
| **EPS pre in €*** ** | **1.13** | **1.54** | **2.67** | **1.35** | **4.02** | **1.54** | **2.89** | **5.56** | **1.50** | | | | | | | | 32.7% | | | | | | | |
| Number of theoretical shares in million | 434.8 | 434.8 | 434.8 | 434.8 | 434.8 | 434.8 | 434.8 | 434.8 | 434.8 | | | | | | | | | | | | | | | |

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments
** only reflects impairments which classified as adjustments
*** for continuing operations

Sum of items may not foot due to rounding.

**Breakdown of depreciation and amortization and adjustments**

| Group<br>€ million | Division | 2019<br>Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | 2020<br>Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Change YoY<br>Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **a) Depreciation and amortization** | | | | | | | | | | | | | | | | | | | | | | | | | |
| **Regular depreciation and amortization*** | **all** | **207.1** | **186.0** | **393.0** | **192.4** | **585.4** | **232.6** | **425.0** | **818.0** | **211.8** | | | | | | | | 2.3% | | | | | | | |
| **Amortization of purchased intangible assets** | | | | | | | | | | | | | | | | | | | | | | | | | |
| Healthcare | HC | 113.3 | 113.4 | 226.7 | 113.2 | 339.8 | 112.9 | 226.0 | 452.7 | 10.1 | | | | | | | | -91.1% | | | | | | | |
| Life Science | LS | 122.0 | 123.8 | 245.8 | 118.0 | 363.9 | 118.2 | 236.2 | 482.1 | 118.9 | | | | | | | | -2.6% | | | | | | | |
| Performance Materials | PM | 31.5 | 32.3 | 63.9 | 32.3 | 96.2 | 88.3 | 120.6 | 184.5 | 88.8 | | | | | | | | 181.4% | | | | | | | |
| **Total** | | **266.9** | **269.5** | **536.4** | **263.5** | **799.9** | **319.4** | **582.9** | **1,119.2** | **217.8** | | | | | | | | -18.4% | | | | | | | |
| **Impairments**** | all | **0.0** | **0.0** | **0.0** | **8.4** | **8.4** | **0.7** | **9.1** | **9.1** | **1.9** | | | | | | | | >1.000% | | | | | | | |
| **Total depreciation and amortization** | | **474.0** | **455.4** | **929.4** | **464.3** | **1,393.7** | **552.6** | **1,016.9** | **1,946.3** | **431.5** | | | | | | | | -9.0% | | | | | | | |
| **b) Adjustments** | | | | | | | | | | | | | | | | | | | | | | | | | |
| **Acquisition costs** | | **0.2** | **0.2** | **0.4** | **0.1** | **0.4** | **83.4** | **83.4** | **83.8** | **19.0** | | | | | | | | >1.000% | | | | | | | |
| **Restructuring costs** | | | | | | | | | | | | | | | | | | | | | | | | | |
| Healthcare | HC | 0.1 | 4.7 | 4.8 | 1.5 | 6.3 | 10.7 | 12.2 | 17.0 | 2.0 | | | | | | | | >1.000% | | | | | | | |
| Life Science | LS | 1.1 | 3.8 | 4.9 | 6.1 | 11.0 | 1.5 | 7.6 | 12.5 | 1.7 | | | | | | | | 53.2% | | | | | | | |
| Performance Materials | PM | 34.1 | 26.3 | 60.5 | 0.9 | 61.3 | -0.4 | 0.4 | 60.9 | 7.4 | | | | | | | | -78.4% | | | | | | | |
| Corporate/Others | CO | 25.9 | 4.3 | 30.2 | 2.0 | 32.2 | -2.2 | -0.2 | 30.0 | 4.3 | | | | | | | | -83.4% | | | | | | | |
| **Total** | | **61.3** | **39.1** | **100.4** | **10.5** | **110.8** | **9.6** | **20.0** | **120.4** | **15.4** | | | | | | | | -74.8% | | | | | | | |
| **Integration costs/IT costs** | | | | | | | | | | | | | | | | | | | | | | | | | |
| Integration Cost | LS/PM/CO | 0.6 | 2.4 | 3.0 | 4.1 | 7.1 | 7.7 | 11.9 | 14.8 | 8.0 | | | | | | | | >1.000% | | | | | | | |
| ERP/HR systems | all | 12.4 | 19.6 | 32.1 | 23.6 | 55.7 | 24.7 | 48.3 | 80.4 | 13.7 | | | | | | | | 10.6% | | | | | | | |
| **Total** | | **13.0** | **22.0** | **35.0** | **27.8** | **62.8** | **32.4** | **60.2** | **95.2** | **21.7** | | | | | | | | 67.0% | | | | | | | |
| **Gain (-)/ losses (+) on the divestment of businesses** | | | | | | | | | | | | | | | | | | | | | | | | | |
| Costs related to former business activities | CO | 0.0 | 0.0 | 0.0 | 0.5 | 0.5 | 0.8 | 1.3 | 1.3 | 1.8 | | | | | | | | >1.000% | | | | | | | |
| Costs related to former business activities | PM | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 | 0.1 | | | | | | | | n.m. | | | | | | | |
| Sale of CH, Allergopharma and others | HC | 0.8 | -3.0 | -2.1 | -6.4 | -8.5 | 4.0 | -2.4 | -4.5 | -31.8 | | | | | | | | n.m. | | | | | | | |
| Costs related to former business activities | LS | 1.0 | 1.2 | 2.2 | 2.2 | 4.4 | 4.5 | 6.7 | 8.9 | 0.0 | | | | | | | | n.m. | | | | | | | |
| **Total** | | **1.8** | **-1.7** | **0.1** | **-3.7** | **-3.6** | **9.5** | **5.8** | **5.9** | **-30.0** | | | | | | | | n.m. | | | | | | | |
| **Other one-time costs** | | | | | | | | | | | | | | | | | | | | | | | | | |
| Others | HC | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | -0.1 | -0.1 | 0.0 | 0.0 | | | | | | | | -100.0% | | | | | | | |
| | LS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | -100.0% | | | | | | | |
| | PM | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | -100.0% | | | | | | | |
| | CO | -0.7 | 5.8 | 5.1 | 4.4 | 9.5 | 3.6 | 8.0 | 13.1 | 7.6 | | | | | | | | n.m. | | | | | | | |
| **Total** | | **-0.6** | **5.9** | **5.3** | **4.4** | **9.6** | **3.5** | **7.9** | **13.2** | **7.6** | | | | | | | | n.m. | | | | | | | |
| **Total adjustments** | | **75.7** | **65.4** | **141.1** | **39.0** | **180.1** | **138.4** | **177.3** | **318.5** | **33.8** | | | | | | | | -55.3% | | | | | | | |

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**

| **Healthcare** | 2019 | | | | | | | | 2020 | | | | | | | | Change YoY | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| € million | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| **Net sales** | **1,480.6** | **1,677.0** | **3,157.6** | **1,755.8** | **4,913.5** | **1,800.3** | **3,556.2** | **6,713.8** | **1,700.5** | | | | | | | | 14.9% | | | | | | | |
| Cost of sales | -324.9 | -421.2 | -746.1 | -417.8 | -1,163.9 | -441.3 | -859.1 | -1,605.2 | -393.4 | | | | | | | | 21.1% | | | | | | | |
| thereof amortization of intangible assets | -0.8 | -1.1 | -1.9 | -0.9 | -2.8 | -0.9 | -1.9 | -3.8 | -0.8 | | | | | | | | -6.2% | | | | | | | |
| Gross profit | 1,155.7 | 1,255.8 | 2,411.5 | 1,338.0 | 3,749.5 | 1,359.0 | 2,697.0 | 5,108.5 | 1,307.1 | | | | | | | | 13.1% | | | | | | | |
| *in % of net sales* | *78.1%* | *74.9%* | *76.4%* | *76.2%* | *76.3%* | *75.5%* | *75.8%* | *76.1%* | *76.9%* | | | | | | | | | | | | | | | |
| SG&A | -647.7 | -516.0 | -1,163.7 | -584.0 | -1,747.7 | -545.8 | -1,129.8 | -2,293.5 | -467.4 | | | | | | | | -27.8% | | | | | | | |
| *in % of net sales* | *43.7%* | *30.8%* | *36.9%* | *33.3%* | *35.6%* | *30.3%* | *31.8%* | *34.2%* | *27.5%* | | | | | | | | | | | | | | | |
| Marketing and selling expenses | -550.4 | -599.4 | -1,149.8 | -560.5 | -1,710.3 | -594.9 | -1,155.4 | -2,305.2 | -423.4 | | | | | | | | -23.1% | | | | | | | |
| thereof amortization of intangible assets (M&S) | -112.2 | -112.2 | -224.3 | -110.8 | -335.1 | -107.4 | -218.2 | -442.5 | -7.5 | | | | | | | | -93.3% | | | | | | | |
| Administration expenses | -87.5 | -84.1 | -171.7 | -82.4 | -254.0 | -90.2 | -172.5 | -344.2 | -79.5 | | | | | | | | -9.2% | | | | | | | |
| Impairment losses and reversals (IFRS 9) | -3.6 | 2.3 | -1.2 | 0.7 | -0.5 | -0.6 | 0.1 | -1.1 | 4.9 | | | | | | | | n.m. | | | | | | | |
| Other operating expenses/income | -6.2 | 165.2 | 159.0 | 58.2 | 217.2 | 139.9 | 198.1 | 357.0 | 30.6 | | | | | | | | n.m. | | | | | | | |
| Impairments** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.1 | -1.1 | -1.1 | -1.9 | | | | | | | | n.m. | | | | | | | |
| Research and development | -380.3 | -394.6 | -774.9 | -428.7 | -1,203.6 | -462.0 | -890.7 | -1,665.6 | -417.4 | | | | | | | | 9.8% | | | | | | | |
| *in % of net sales* | *25.7%* | *23.5%* | *24.5%* | *24.4%* | *24.5%* | *25.7%* | *25.0%* | *24.8%* | *24.5%* | | | | | | | | | | | | | | | |
| thereof amortization of intangible assets (R&D) | -0.4 | -0.2 | -0.6 | -1.5 | -2.0 | -4.6 | -6.0 | -6.6 | -1.9 | | | | | | | | 407.2% | | | | | | | |
| **EBIT** | **127.8** | **345.1** | **472.9** | **325.4** | **798.2** | **351.2** | **676.6** | **1,149.5** | **422.3** | | | | | | | | 230.5% | | | | | | | |
| *in % of net sales* | *8.6%* | *20.6%* | *15.0%* | *18.5%* | *16.2%* | *19.5%* | *19.0%* | *17.1%* | *24.8%* | | | | | | | | | | | | | | | |
| Depreciation and amortization | 201.3 | 177.4 | 378.7 | 178.2 | 556.9 | 190.0 | 368.2 | 746.9 | 78.9 | | | | | | | | -60.8% | | | | | | | |
| **EBITDA** | **329.1** | **522.5** | **851.6** | **503.5** | **1,355.1** | **541.2** | **1,044.8** | **1,896.4** | **501.0** | | | | | | | | 52.3% | | | | | | | |
| *in % of net sales* | *22.2%* | *31.2%* | *27.0%* | *28.7%* | *27.6%* | *30.1%* | *29.4%* | *28.2%* | *29.5%* | | | | | | | | | | | | | | | |
| **EBITDA pre** | **332.0** | **527.8** | **859.8** | **500.8** | **1,360.6** | **561.1** | **1,061.9** | **1,921.7** | **472.1** | | | | | | | | 42.2% | | | | | | | |
| *in % of net sales* | *22.4%* | *31.5%* | *27.2%* | *28.5%* | *27.7%* | *31.2%* | *29.9%* | *28.6%* | *27.8%* | | | | | | | | | | | | | | | |
| **Reconciliation to EBITDA pre** | | | | | | | | | | | | | | | | | | | | | | | | |
| EBITDA | 329.1 | 522.5 | 851.6 | 503.5 | 1,355.1 | 541.2 | 1,044.8 | 1,896.4 | 501.0 | | | | | | | | 52.3% | | | | | | | |
| **Adjustments** | | | | | | | | | | | | | | | | | | | | | | | | |
| thereof: Cost of Sales | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 | 0.2 | | | | | | | | n.m. | | | | | | | |
| thereof: Marketing and selling expenses | 0.0 | 0.1 | 0.1 | 2.4 | 2.5 | 0.1 | 2.5 | 2.6 | 0.8 | | | | | | | | n.m. | | | | | | | |
| thereof: Administration expenses | 1.7 | 2.9 | 4.6 | 1.6 | 6.2 | 9.3 | 10.9 | 15.4 | 1.0 | | | | | | | | -39.5% | | | | | | | |
| thereof: Other operating expenses/income | 1.2 | 2.3 | 3.6 | -7.5 | -4.0 | 8.9 | 1.4 | 5.0 | -30.9 | | | | | | | | n.m. | | | | | | | |
| thereof: Research and development | 0.0 | 0.0 | 0.0 | 0.8 | 0.8 | 1.4 | 2.2 | 2.2 | 0.0 | | | | | | | | n.m. | | | | | | | |
| **Total** | **2.9** | **5.3** | **8.2** | **-2.8** | **5.5** | **19.9** | **17.1** | **25.4** | **-28.9** | | | | | | | | n.m. | | | | | | | |
| **EBITDA pre** | **332.0** | **527.8** | **859.8** | **500.8** | **1,360.6** | **561.1** | **1,061.9** | **1,921.7** | **472.1** | | | | | | | | 42.2% | | | | | | | |

Sum of items may not foot due to rounding.

**Detailed reconciliation - Healthcare**

| € million | 2019 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | 2020 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Change YoY Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **EBIT** | **127.8** | **345.1** | **472.9** | **325.4** | **798.2** | **351.2** | **676.6** | **1,149.5** | **422.3** | | | | | | | | 230.5% | | | | | | | |
| Regular depreciation and amortization* | 88.0 | 64.1 | 152.0 | 65.0 | 217.0 | 76.1 | 141.1 | 293.1 | 66.8 | | | | | | | | -24.0% | | | | | | | |
| Amortization of purchased intangible assets | 113.3 | 113.4 | 226.7 | 113.2 | 339.8 | 112.9 | 226.0 | 452.7 | 10.1 | | | | | | | | -91.1% | | | | | | | |
| Impairments** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 1.1 | 1.1 | 1.9 | | | | | | | | n.m. | | | | | | | |
| **Total depreciation and amortization** | **201.3** | **177.4** | **378.7** | **178.2** | **556.9** | **190.0** | **368.2** | **746.9** | **78.8** | | | | | | | | -60.9% | | | | | | | |
| **EBITDA** | **329.1** | **522.5** | **851.6** | **503.5** | **1,355.1** | **541.2** | **1,044.8** | **1,896.4** | **501.0** | | | | | | | | 52.3% | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| **Adjustments** | | | | | | | | | | | | | | | | | | | | | | | | |
| **Acquisition costs** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | | | | | | | | n.m. | | | | | | | |
| **Restructuring costs** | | | | | | | | | | | | | | | | | | | | | | | | |
| Restructuring costs | 0.1 | 4.7 | 4.8 | 1.5 | 6.3 | 10.7 | 12.2 | 17.0 | 2.0 | | | | | | | | >1.000% | | | | | | | |
| **Total** | **0.1** | **4.7** | **4.8** | **1.5** | **6.3** | **10.7** | **12.2** | **17.0** | **2.0** | | | | | | | | >1.000% | | | | | | | |
| **Integration costs/IT costs** | | | | | | | | | | | | | | | | | | | | | | | | |
| Integration Cost | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | n.m. | | | | | | | |
| ERP/HR systems | 1.9 | 3.6 | 5.4 | 2.1 | 7.5 | 5.3 | 7.4 | 12.8 | 0.9 | | | | | | | | -50.9% | | | | | | | |
| **Total** | **1.9** | **3.6** | **5.4** | **2.1** | **7.5** | **5.3** | **7.4** | **12.8** | **0.9** | | | | | | | | -50.9% | | | | | | | |
| **Gain (-)/ losses (+) on the divestment of businesses** | | | | | | | | | | | | | | | | | | | | | | | | |
| Sale of Kuvan and Biosimilars | 0.0 | -4.9 | -4.8 | 0.0 | -4.8 | 1.0 | 1.0 | -3.8 | 0.1 | | | | | | | | 43.5% | | | | | | | |
| Sale of Consumer Health | 0.8 | 1.9 | 2.7 | -6.4 | -3.7 | 2.9 | -3.5 | -0.8 | 4.6 | | | | | | | | 494.6% | | | | | | | |
| Sale of Allergopharma | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -36.5 | | | | | | | | n.m. | | | | | | | |
| Others | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | -0.1 | 0.0 | | | | | | | | n.m. | | | | | | | |
| **Total** | **0.8** | **-3.0** | **-2.1** | **-6.4** | **-8.5** | **4.0** | **-2.4** | **-4.5** | **-31.8** | | | | | | | | n.m. | | | | | | | |
| **Other one-time costs** | | | | | | | | | | | | | | | | | | | | | | | | |
| Others | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | -0.1 | -0.1 | 0.0 | 0.0 | | | | | | | | -100.0% | | | | | | | |
| **Total** | **0.1** | **0.1** | **0.1** | **0.0** | **0.1** | **-0.1** | **-0.1** | **0.0** | **0.0** | | | | | | | | -100.0% | | | | | | | |
| **Total adjustments** | **2.9** | **5.3** | **8.2** | **-2.8** | **5.5** | **19.9** | **17.1** | **25.4** | **-28.9** | | | | | | | | n.m. | | | | | | | |
| **EBITDA pre** | **332.0** | **527.8** | **859.8** | **500.8** | **1,360.6** | **561.1** | **1,061.9** | **1,921.7** | **472.1** | | | | | | | | 42.2% | | | | | | | |

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**
**Life Science**
€ million

| | 2019 | | | | | | | | 2020 | | | | | | | | Change YoY | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| **Net sales** | **1,661.0** | **1,705.5** | **3,366.5** | **1,715.2** | **5,081.7** | **1,782.6** | **3,497.9** | **6,864.3** | **1,768.9** | | | | | | | | 6.5% | | | | | | | |
| Cost of sales | -719.0 | -723.9 | -1,442.9 | -747.8 | -2,190.7 | -770.8 | -1,518.6 | -2,961.5 | -744.5 | | | | | | | | 3.5% | | | | | | | |
| thereof amortization of intangible assets | -14.4 | -14.5 | -28.9 | -14.6 | -43.5 | -15.0 | -29.6 | -58.5 | -15.0 | | | | | | | | 3.7% | | | | | | | |
| Gross profit | 942.0 | 981.6 | 1,923.6 | 967.4 | 2,891.0 | 1,011.8 | 1,979.2 | 3,902.8 | 1,024.4 | | | | | | | | 8.8% | | | | | | | |
| *in % of net sales* | *56.7%* | *57.6%* | *57.1%* | *56.4%* | *56.9%* | *56.8%* | *56.6%* | *56.9%* | *57.9%* | | | | | | | | | | | | | | | |
| SG&A | -566.8 | -590.5 | -1,157.3 | -584.2 | -1,741.4 | -604.7 | -1,188.9 | -2,346.2 | -603.8 | | | | | | | | 6.5% | | | | | | | |
| *in % of net sales* | *34.1%* | *34.6%* | *34.4%* | *34.1%* | *34.3%* | *33.9%* | *34.0%* | *34.2%* | *34.1%* | | | | | | | | | | | | | | | |
| Marketing and selling expenses | -469.5 | -489.8 | -959.3 | -474.4 | -1,433.7 | -489.9 | -964.3 | -1,923.6 | -497.5 | | | | | | | | 6.0% | | | | | | | |
| thereof amortization of intangible assets (M&S) | -107.6 | -109.3 | -216.9 | -103.4 | -320.3 | -103.2 | -206.6 | -423.5 | -104.0 | | | | | | | | -3.4% | | | | | | | |
| Administration expenses | -87.5 | -68.4 | -155.9 | -83.2 | -239.1 | -101.9 | -185.1 | -341.1 | -89.2 | | | | | | | | 1.9% | | | | | | | |
| Impairment losses and reversals (IFRS 9) | 0.0 | -0.3 | -0.3 | -2.6 | -2.9 | -3.8 | -6.4 | -6.7 | 0.4 | | | | | | | | >1.000% | | | | | | | |
| Other operating expenses/income | -9.8 | -32.0 | -41.8 | -23.9 | -65.7 | -9.1 | -33.1 | -74.8 | -17.6 | | | | | | | | 80.1% | | | | | | | |
| Impairments** | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | 0.0 | -0.1 | -0.1 | 0.0 | | | | | | | | -100.0% | | | | | | | |
| Research and development | -61.8 | -69.4 | -131.2 | -67.3 | -198.5 | -77.7 | -145.0 | -276.2 | -75.3 | | | | | | | | 21.9% | | | | | | | |
| *in % of net sales* | *3.7%* | *4.1%* | *3.9%* | *3.9%* | *3.9%* | *4.4%* | *4.1%* | *4.0%* | *4.3%* | | | | | | | | | | | | | | | |
| thereof amortization of intangible assets (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | 135.8% | | | | | | | |
| **EBIT** | **313.4** | **321.7** | **635.1** | **316.0** | **951.1** | **329.3** | **645.3** | **1,280.4** | **345.3** | | | | | | | | 10.2% | | | | | | | |
| *in % of net sales* | *18.9%* | *18.9%* | *18.9%* | *18.4%* | *18.7%* | *18.5%* | *18.4%* | *18.7%* | *19.5%* | | | | | | | | | | | | | | | |
| Depreciation and amortization | 193.5 | 196.6 | 390.1 | 194.9 | 584.9 | 204.4 | 399.2 | 789.3 | 196.0 | | | | | | | | 1.3% | | | | | | | |
| **EBITDA** | **506.8** | **518.3** | **1,025.1** | **510.9** | **1,536.0** | **533.7** | **1,044.6** | **2,069.7** | **541.3** | | | | | | | | 6.8% | | | | | | | |
| *in % of net sales* | *30.5%* | *30.4%* | *30.5%* | *29.8%* | *30.2%* | *29.9%* | *29.9%* | *30.2%* | *30.6%* | | | | | | | | | | | | | | | |
| **EBITDA pre** | **515.7** | **533.3** | **1,049.0** | **531.1** | **1,580.1** | **548.7** | **1,079.8** | **2,128.9** | **552.7** | | | | | | | | 7.2% | | | | | | | |
| *in % of net sales* | *31.0%* | *31.3%* | *31.2%* | *31.0%* | *31.1%* | *30.8%* | *30.9%* | *31.0%* | *31.2%* | | | | | | | | | | | | | | | |
| **Reconciliation to EBITDA pre** | | | | | | | | | | | | | | | | | | | | | | | | |
| EBITDA | 506.8 | 518.3 | 1,025.1 | 510.9 | 1,536.0 | 533.7 | 1,044.6 | 2,069.7 | 541.3 | | | | | | | | 6.8% | | | | | | | |
| **Adjustments** | | | | | | | | | | | | | | | | | | | | | | | | |
| thereof: Cost of Sales | 0.7 | 0.5 | 1.2 | 2.3 | 3.4 | 1.6 | 3.8 | 5.0 | 0.2 | | | | | | | | -65.8% | | | | | | | |
| thereof: Marketing and selling expenses | 0.5 | 0.1 | 0.7 | 0.9 | 1.6 | 0.0 | 0.9 | 1.5 | 0.1 | | | | | | | | -85.7% | | | | | | | |
| thereof: Administration expenses | 6.1 | -0.6 | 5.5 | 6.0 | 11.6 | 22.1 | 28.2 | 33.7 | 9.3 | | | | | | | | 52.0% | | | | | | | |
| thereof: Other operating expenses/income | 1.4 | 14.9 | 16.3 | 11.1 | 27.4 | -8.7 | 2.4 | 18.8 | 1.8 | | | | | | | | 28.7% | | | | | | | |
| thereof: Research and development | 0.2 | 0.0 | 0.2 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | | | | | | | | -100.0% | | | | | | | |
| **Total** | **8.9** | **15.0** | **23.9** | **20.3** | **44.1** | **15.0** | **35.3** | **59.1** | **11.4** | | | | | | | | 27.5% | | | | | | | |
| **EBITDA pre** | **515.7** | **533.3** | **1,049.0** | **531.1** | **1,580.1** | **548.7** | **1,079.8** | **2,128.9** | **552.7** | | | | | | | | 7.2% | | | | | | | |

Sum of items may not foot due to rounding.

**Detailed reconciliation - Life Science**

| € million | 2019 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | 2020 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Change YoY Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **EBIT** | **313.4** | **321.7** | **635.1** | **316.0** | **951.1** | **329.3** | **645.3** | **1,280.4** | **345.3** | | | | | | | | 10.2% | | | | | | | |
| Regular depreciation and amortization* | 71.4 | 72.8 | 144.2 | 76.8 | 221.0 | 86.2 | 162.9 | 307.1 | 77.1 | | | | | | | | 8.0% | | | | | | | |
| Amortization of purchased intangible assets | 122.0 | 123.8 | 245.8 | 118.0 | 363.9 | 118.2 | 236.2 | 482.1 | 118.9 | | | | | | | | -2.6% | | | | | | | |
| Impairments** | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | | | | | | | | -100.0% | | | | | | | |
| **Total depreciation and amortization** | **193.5** | **196.6** | **390.1** | **194.9** | **584.9** | **204.4** | **399.2** | **789.3** | **196.0** | | | | | | | | 1.3% | | | | | | | |
| **EBITDA** | **506.8** | **518.3** | **1,025.1** | **510.9** | **1,536.0** | **533.7** | **1,044.6** | **2,069.7** | **541.3** | | | | | | | | 6.8% | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| **Adjustments** | | | | | | | | | | | | | | | | | | | | | | | | |
| **Acquisition costs** | **0.2** | **0.2** | **0.4** | **0.1** | **0.4** | **1.6** | **1.7** | **2.0** | **0.0** | | | | | | | | -85.7% | | | | | | | |
| **Restructuring costs** | | | | | | | | | | | | | | | | | | | | | | | | |
| Restructuring costs | 1.1 | 3.8 | 4.9 | 6.1 | 11.0 | 1.5 | 7.6 | 12.5 | 1.7 | | | | | | | | 53.2% | | | | | | | |
| **Total** | **1.1** | **3.8** | **4.9** | **6.1** | **11.0** | **1.5** | **7.6** | **12.5** | **1.7** | | | | | | | | 53.2% | | | | | | | |
| **Integration costs/IT costs** | | | | | | | | | | | | | | | | | | | | | | | | |
| Integration Cost | 0.6 | 1.0 | 1.5 | 0.8 | 2.3 | 0.2 | 1.0 | 2.5 | 0.8 | | | | | | | | 44.9% | | | | | | | |
| ERP/HR systems | 6.0 | 8.8 | 14.8 | 11.2 | 26.0 | 7.1 | 18.3 | 33.1 | 8.8 | | | | | | | | 46.1% | | | | | | | |
| **Total** | **6.6** | **9.7** | **16.3** | **12.0** | **28.3** | **7.3** | **19.3** | **35.7** | **9.7** | | | | | | | | 46.0% | | | | | | | |
| **Gain (-)/ losses (+) on the divestment of businesses** | | | | | | | | | | | | | | | | | | | | | | | | |
| Costs related to former business activities | 1.0 | 1.2 | 2.2 | 2.2 | 4.4 | 4.5 | 6.7 | 8.9 | 0.0 | | | | | | | | n.m. | | | | | | | |
| **Total** | **1.0** | **1.2** | **2.2** | **2.2** | **4.4** | **4.5** | **6.7** | **8.9** | **0.0** | | | | | | | | n.m. | | | | | | | |
| **Other one-time costs** | | | | | | | | | | | | | | | | | | | | | | | | |
| Others | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | -100.0% | | | | | | | |
| **Total** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | | | | | | | | -100.0% | | | | | | | |
| **Total adjustments** | **8.9** | **15.0** | **23.9** | **20.3** | **44.1** | **15.0** | **35.3** | **59.1** | **11.4** | | | | | | | | 28.0% | | | | | | | |
| **EBITDA pre** | **515.7** | **533.3** | **1,049.0** | **531.1** | **1,580.1** | **548.7** | **1,079.8** | **2,128.9** | **552.7** | | | | | | | | 7.2% | | | | | | | |

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**
**Performance Materials**

| € million | 2019 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | 2020 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Change YoY Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Net sales** | **604.1** | **589.0** | **1,193.1** | **582.7** | **1,775.8** | **797.9** | **1,380.5** | **2,573.6** | **900.3** | | | | | | | | 49.0% | | | | | | | |
| Cost of sales | -337.9 | -306.9 | -644.8 | -314.7 | -959.5 | -477.2 | -792.0 | -1,436.8 | -515.1 | | | | | | | | 52.4% | | | | | | | |
| thereof amortization of intangible assets | -28.2 | -28.2 | -56.4 | -28.5 | -84.9 | -41.0 | -69.5 | -125.9 | -41.0 | | | | | | | | 45.3% | | | | | | | |
| Gross profit | 266.3 | 282.0 | 548.3 | 267.9 | 816.2 | 320.6 | 588.6 | 1,136.9 | 385.3 | | | | | | | | 44.7% | | | | | | | |
| *in % of net sales* | *44.1%* | *47.9%* | *46.0%* | *46.0%* | *46.0%* | *40.2%* | *42.6%* | *44.2%* | *42.8%* | | | | | | | | | | | | | | | |
| SG&A | -99.3 | -108.1 | -207.4 | -121.8 | -329.2 | -233.3 | -355.1 | -562.6 | -197.6 | | | | | | | | 99.0% | | | | | | | |
| *in % of net sales* | *16.4%* | *18.4%* | *17.4%* | *20.9%* | *18.5%* | *29.2%* | *25.7%* | *21.9%* | *21.9%* | | | | | | | | | | | | | | | |
| Marketing and selling expenses | -65.9 | -66.1 | -132.0 | -61.0 | -193.0 | -136.0 | -197.0 | -329.0 | -135.6 | | | | | | | | 105.8% | | | | | | | |
| thereof amortization of intangible assets (M&S) | -2.8 | -3.7 | -6.4 | -3.4 | -9.8 | -46.8 | -50.2 | -56.6 | -47.3 | | | | | | | | >1.000% | | | | | | | |
| Administration expenses | -23.4 | -25.3 | -48.7 | -29.6 | -78.3 | -39.3 | -69.0 | -117.7 | -38.4 | | | | | | | | 63.8% | | | | | | | |
| Impairment losses and reversals (IFRS 9) | -0.1 | -0.1 | -0.1 | 0.5 | 0.4 | 0.1 | 0.6 | 0.5 | 0.6 | | | | | | | | n.m. | | | | | | | |
| Other operating expenses/income | -9.9 | -16.7 | -26.6 | -31.6 | -58.2 | -58.2 | -89.8 | -116.4 | -24.2 | | | | | | | | 144.8% | | | | | | | |
| Impairments** | 0.0 | 0.0 | 0.0 | -8.3 | -8.3 | 0.9 | -7.4 | -7.4 | 0.0 | | | | | | | | n.m. | | | | | | | |
| Research and development | -71.8 | -74.4 | -146.1 | -48.1 | -194.2 | -73.0 | -121.1 | -267.2 | -71.3 | | | | | | | | -0.6% | | | | | | | |
| *in % of net sales* | *11.9%* | *12.6%* | *12.2%* | *8.3%* | *10.9%* | *9.2%* | *8.8%* | *10.4%* | *7.9%* | | | | | | | | | | | | | | | |
| thereof amortization of intangible assets (R&D) | -0.6 | -0.5 | -1.1 | -0.5 | -1.5 | -0.5 | -1.0 | -2.0 | -0.5 | | | | | | | | -22.2% | | | | | | | |
| **EBIT** | **95.2** | **99.5** | **194.8** | **98.1** | **292.8** | **14.3** | **112.3** | **307.1** | **116.3** | | | | | | | | 22.1% | | | | | | | |
| *in % of net sales* | *15.8%* | *16.9%* | *16.3%* | *16.8%* | *16.5%* | *1.8%* | *8.1%* | *11.9%* | *12.9%* | | | | | | | | | | | | | | | |
| Depreciation and amortization | 61.9 | 61.7 | 123.6 | 71.3 | 194.9 | 135.1 | 206.4 | 330.0 | 134.7 | | | | | | | | 117.5% | | | | | | | |
| **EBITDA** | **157.1** | **161.2** | **318.3** | **169.4** | **487.7** | **149.3** | **318.7** | **637.0** | **251.0** | | | | | | | | 59.7% | | | | | | | |
| *in % of net sales* | *26.0%* | *27.4%* | *26.7%* | *29.1%* | *27.5%* | *18.7%* | *23.1%* | *24.8%* | *27.9%* | | | | | | | | | | | | | | | |
| **EBITDA pre** | **192.6** | **190.3** | **382.9** | **177.5** | **560.4** | **243.0** | **420.5** | **803.4** | **285.5** | | | | | | | | 48.3% | | | | | | | |
| *in % of net sales* | *31.9%* | *32.3%* | *32.1%* | *30.5%* | *31.6%* | *30.5%* | *30.5%* | *31.2%* | *31.7%* | | | | | | | | | | | | | | | |
| **Reconciliation to EBITDA pre** | | | | | | | | | | | | | | | | | | | | | | | | |
| EBITDA | 157.1 | 161.2 | 318.3 | 169.4 | 487.7 | 149.3 | 318.7 | 637.0 | 251.0 | | | | | | | | 59.7% | | | | | | | |
| **Adjustments** | | | | | | | | | | | | | | | | | | | | | | | | |
| thereof: Cost of Sales | 15.3 | 3.0 | 18.2 | 5.0 | 23.3 | 27.7 | 32.7 | 50.9 | 19.8 | | | | | | | | 29.6% | | | | | | | |
| thereof: Marketing and selling expenses | 2.4 | 4.6 | 7.0 | -1.4 | 5.6 | 0.4 | -0.9 | 6.1 | 1.3 | | | | | | | | -46.5% | | | | | | | |
| thereof: Administration expenses | 1.3 | 0.9 | 2.2 | 6.8 | 9.0 | 1.6 | 8.4 | 10.6 | 0.3 | | | | | | | | -75.7% | | | | | | | |
| thereof: Other operating expenses/income | 0.9 | 3.6 | 4.5 | 8.1 | 12.7 | 59.7 | 67.8 | 72.3 | 14.4 | | | | | | | | >1.000% | | | | | | | |
| thereof: Research and development | 15.5 | 17.0 | 32.6 | -10.5 | 22.1 | 4.4 | -6.2 | 26.4 | -1.3 | | | | | | | | n.m. | | | | | | | |
| **Total** | **35.4** | **29.1** | **64.6** | **8.1** | **72.6** | **93.7** | **101.8** | **166.4** | **34.6** | | | | | | | | -2.4% | | | | | | | |
| **EBITDA pre** | **192.6** | **190.3** | **382.9** | **177.5** | **560.4** | **243.0** | **420.5** | **803.4** | **285.5** | | | | | | | | 48.3% | | | | | | | |

Sum of items may not foot due to rounding.

**Detailed reconciliation - Performance Materials**

| € million | 2019 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | 2020 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Change YoY Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **EBIT** | **95.2** | **99.5** | **194.8** | **98.1** | **292.8** | **14.3** | **112.3** | **307.1** | **116.3** | | | | | | | | 22.1% | | | | | | | |
| Regular depreciation and amortization* | 30.4 | 29.4 | 59.7 | 30.7 | 90.4 | 47.6 | 78.3 | 138.0 | 45.9 | | | | | | | | 51.2% | | | | | | | |
| Amortization of purchased intangible assets | 31.5 | 32.3 | 63.9 | 32.3 | 96.2 | 88.3 | 120.6 | 184.5 | 88.8 | | | | | | | | 181.4% | | | | | | | |
| Impairments** | 0.0 | 0.0 | 0.0 | 8.3 | 8.3 | -0.9 | 7.4 | 7.4 | 0.0 | | | | | | | | n.m. | | | | | | | |
| **Total depreciation and amortization** | **61.9** | **61.7** | **123.6** | **71.3** | **194.9** | **135.1** | **206.4** | **330.0** | **134.7** | | | | | | | | 117.5% | | | | | | | |
| **EBITDA** | **157.1** | **161.2** | **318.3** | **169.4** | **487.7** | **149.3** | **318.7** | **637.0** | **251.0** | | | | | | | | 59.7% | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| **Adjustments** | | | | | | | | | | | | | | | | | | | | | | | | |
| **Acquisition costs** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **81.8** | **81.8** | **81.8** | **19.0** | | | | | | | | n.m. | | | | | | | |
| **Restructuring costs** | | | | | | | | | | | | | | | | | | | | | | | | |
| Restructuring costs | 34.1 | 26.3 | 60.5 | 0.9 | 61.3 | -0.4 | 0.4 | 60.9 | 7.4 | | | | | | | | -78.4% | | | | | | | |
| **Total** | **34.1** | **26.3** | **60.5** | **0.9** | **61.3** | **-0.4** | **0.4** | **60.9** | **7.4** | | | | | | | | -78.4% | | | | | | | |
| **Integration costs/IT costs** | | | | | | | | | | | | | | | | | | | | | | | | |
| Integration Cost | 0.0 | 1.3 | 1.3 | 3.3 | 4.6 | 7.5 | 10.8 | 12.1 | 7.1 | | | | | | | | >1.000% | | | | | | | |
| ERP/HR systems | 1.3 | 1.5 | 2.8 | 3.9 | 6.7 | 4.7 | 8.6 | 11.4 | 1.1 | | | | | | | | -18.7% | | | | | | | |
| **Total** | **1.3** | **2.8** | **4.1** | **7.2** | **11.3** | **12.2** | **19.4** | **23.5** | **8.2** | | | | | | | | 525.0% | | | | | | | |
| **Gain (-)/ losses (+) on the divestment of businesses** | | | | | | | | | | | | | | | | | | | | | | | | |
| Costs related to former business activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 | 0.1 | | | | | | | | n.m. | | | | | | | |
| **Total** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.2** | **0.2** | **0.2** | **0.1** | | | | | | | | n.m. | | | | | | | |
| **Other one-time costs** | | | | | | | | | | | | | | | | | | | | | | | | |
| Others | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | -100.0% | | | | | | | |
| **Total** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | | | | | | | | -100.0% | | | | | | | |
| **Total adjustments** | **35.4** | **29.1** | **64.6** | **8.1** | **72.6** | **93.7** | **101.8** | **166.4** | **34.6** | | | | | | | | -2.4% | | | | | | | |
| **EBITDA pre** | **192.6** | **190.3** | **382.9** | **177.5** | **560.4** | **243.0** | **420.5** | **803.4** | **285.5** | | | | | | | | 48.3% | | | | | | | |

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**
**Corporate/Others**

| € million | 2019 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | 2020 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Change YoY Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Net sales** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | | | | | | | | n.m. | | | | | | | |
| Cost of sales | -1.8 | -2.4 | -4.1 | 2.5 | -1.7 | -1.1 | 1.4 | -2.8 | -0.6 | | | | | | | | -65.0% | | | | | | | |
| thereof amortization of intangible assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | n.m. | | | | | | | |
| Gross profit | -1.8 | -2.4 | -4.1 | 2.5 | -1.7 | -1.1 | 1.4 | -2.7 | -0.6 | | | | | | | | -65.0% | | | | | | | |
| SG&A | -143.0 | -130.7 | -273.7 | -119.6 | -393.3 | -161.8 | -281.4 | -555.1 | -152.2 | | | | | | | | 6.4% | | | | | | | |
| Marketing and selling expenses | -5.0 | -1.6 | -6.6 | -4.4 | -11.0 | -7.7 | -12.1 | -18.7 | -2.2 | | | | | | | | -55.5% | | | | | | | |
| thereof amortization of intangible assets (M&S) | -0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | -99.7% | | | | | | | |
| Administration expenses | -84.6 | -91.3 | -175.8 | -72.3 | -248.1 | -102.9 | -175.2 | -351.0 | -81.6 | | | | | | | | -3.5% | | | | | | | |
| Impairment losses and reversals (IFRS 9) | -0.3 | 0.2 | -0.1 | 0.2 | 0.1 | -0.3 | -0.1 | -0.2 | 0.1 | | | | | | | | n.m. | | | | | | | |
| Other operating expenses/income | -53.2 | -38.0 | -91.2 | -43.0 | -134.2 | -50.9 | -94.0 | -185.1 | -68.5 | | | | | | | | 28.8% | | | | | | | |
| Impairments** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.4 | -0.4 | -0.4 | 0.0 | | | | | | | | n.m. | | | | | | | |
| Research and development | -12.8 | -14.8 | -27.6 | -14.3 | -41.9 | -17.3 | -31.6 | -59.2 | -15.0 | | | | | | | | 17.9% | | | | | | | |
| thereof amortization of intangible assets (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | n.m. | | | | | | | |
| **EBIT** | **-157.5** | **-147.9** | **-305.4** | **-131.4** | **-436.8** | **-180.2** | **-311.5** | **-617.0** | **-167.9** | | | | | | | | 6.6% | | | | | | | |
| Depreciation and amortization | 17.3 | 19.7 | 37.1 | 19.9 | 57.0 | 23.2 | 43.1 | 80.2 | 22.1 | | | | | | | | 27.5% | | | | | | | |
| **EBITDA** | **-140.2** | **-128.1** | **-268.3** | **-111.5** | **-379.8** | **-157.0** | **-268.5** | **-536.8** | **-145.8** | | | | | | | | 4.0% | | | | | | | |
| **EBITDA pre** | **-111.8** | **-112.1** | **-223.9** | **-98.1** | **-322.0** | **-147.2** | **-245.3** | **-469.2** | **-129.1** | | | | | | | | 15.5% | | | | | | | |
| **Reconciliation to EBITDA pre** | | | | | | | | | | | | | | | | | | | | | | | | |
| EBITDA | -140.2 | -128.1 | -268.3 | -111.5 | -379.8 | -157.0 | -268.5 | -536.8 | -145.8 | | | | | | | | 4.0% | | | | | | | |
| **Adjustments** | | | | | | | | | | | | | | | | | | | | | | | | |
| thereof: Cost of Sales | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | n.m. | | | | | | | |
| thereof: Marketing and selling expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | | | | | | | | n.m. | | | | | | | |
| thereof: Administration expenses | 27.6 | 7.4 | 35.0 | 7.5 | 42.5 | 6.8 | 14.3 | 49.3 | 5.7 | | | | | | | | -79.2% | | | | | | | |
| thereof: Other operating expenses/income | 0.8 | 8.6 | 9.4 | 6.0 | 15.4 | 2.9 | 8.8 | 18.2 | 11.0 | | | | | | | | >1.000% | | | | | | | |
| thereof: Research and development | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | n.m. | | | | | | | |
| **Total** | **28.4** | **16.0** | **44.4** | **13.4** | **57.8** | **9.8** | **23.2** | **67.6** | **16.7** | | | | | | | | -41.2% | | | | | | | |
| **EBITDA pre** | **-111.8** | **-112.1** | **-223.9** | **-98.1** | **-322.0** | **-147.2** | **-245.3** | **-469.2** | **-129.1** | | | | | | | | 15.5% | | | | | | | |

Sum of items may not foot due to rounding.

**Detailed reconciliation - Corporate / Others**

| € million | 2019 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | 2020 Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Change YoY Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **EBIT** | **-157.5** | **-147.9** | **-305.4** | **-131.4** | **-436.8** | **-180.2** | **-311.5** | **-617.0** | **-167.9** | | | | | | | | 6.6% | | | | | | | |
| Regular depreciation and amortization* | 17.2 | 19.9 | 37.1 | 19.9 | 57.0 | 22.8 | 42.6 | 79.7 | 22.1 | | | | | | | | 28.2% | | | | | | | |
| Amortization of purchased intangible assets | 0.1 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | -99.7% | | | | | | | |
| Impairments** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.4 | 0.4 | 0.0 | | | | | | | | n.m. | | | | | | | |
| **Total depreciation and amortization** | **17.3** | **19.8** | **37.1** | **19.9** | **57.0** | **23.2** | **43.1** | **80.2** | **22.1** | | | | | | | | 27.5% | | | | | | | |
| **EBITDA** | **-140.2** | **-128.1** | **-268.3** | **-111.5** | **-379.8** | **-157.0** | **-268.5** | **-536.8** | **-145.8** | | | | | | | | 4.0% | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| **Adjustments** | | | | | | | | | | | | | | | | | | | | | | | | |
| **Acquisition costs** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | | | | | | | | n.m. | | | | | | | |
| **Restructuring costs** | | | | | | | | | | | | | | | | | | | | | | | | |
| Restructuring costs | 25.9 | 4.3 | 30.2 | 2.0 | 32.2 | -2.2 | -0.2 | 30.0 | 4.3 | | | | | | | | -83.4% | | | | | | | |
| **Total** | **25.9** | **4.3** | **30.2** | **2.0** | **32.2** | **-2.2** | **-0.2** | **30.0** | **4.3** | | | | | | | | -83.4% | | | | | | | |
| **IT project costs** | | | | | | | | | | | | | | | | | | | | | | | | |
| Integration Cost | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 | 0.0 | 0.1 | 0.2 | 0.0 | | | | | | | | | | | | | | | |
| ERP/HR systems | 3.2 | 5.8 | 9.0 | 6.4 | 15.4 | 7.6 | 14.0 | 23.0 | 2.9 | | | | | | | | -8.1% | | | | | | | |
| **Total** | **3.2** | **5.9** | **9.1** | **6.5** | **15.6** | **7.6** | **14.1** | **23.2** | **3.0** | | | | | | | | -6.7% | | | | | | | |
| **Gain (-)/ losses (+) on the divestment of businesses** | | | | | | | | | | | | | | | | | | | | | | | | |
| Costs related to former business activities | 0.0 | 0.0 | 0.0 | 0.5 | 0.5 | 0.8 | 1.3 | 1.3 | 1.8 | | | | | | | | >1.000% | | | | | | | |
| **Total** | **0.0** | **0.0** | **0.0** | **0.5** | **0.5** | **0.8** | **1.3** | **1.3** | **1.8** | | | | | | | | >1.000% | | | | | | | |
| **Other one-time costs** | | | | | | | | | | | | | | | | | | | | | | | | |
| Others | -0.7 | 5.8 | 5.1 | 4.4 | 9.5 | 3.6 | 8.0 | 13.1 | 7.6 | | | | | | | | n.m. | | | | | | | |
| **Total** | **-0.7** | **5.8** | **5.1** | **4.4** | **9.5** | **3.6** | **8.0** | **13.1** | **7.6** | | | | | | | | n.m. | | | | | | | |
| **Total adjustments** | **28.4** | **16.0** | **44.4** | **13.4** | **57.8** | **9.8** | **23.2** | **67.6** | **16.7** | | | | | | | | -41.2% | | | | | | | |
| **EBITDA pre** | **-111.8** | **-112.1** | **-223.9** | **-98.1** | **-322.0** | **-147.2** | **-245.3** | **-469.2** | **-129.1** | | | | | | | | 15.5% | | | | | | | |

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

**Cash Flow Statement Merck KGaA, Darmstadt, Germany**

| **Group** | **2019** | | | | | | | | **2020** | | | | | | | | Change YoY | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| € million | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| **Profit after tax** | 189.5 | 470.9 | 660.4 | 341.9 | 1,002.3 | 321.3 | 663.2 | 1,323.6 | 458.0 | | | | | | | | 141.7% | | | | | | | |
| Depreciation/amortization/impairment losses/write-ups | 474.0 | 453.0 | 927.0 | 464.2 | 1,391.3 | 552.4 | 1,016.6 | 1,943.6 | 431.5 | | | | | | | | -9.0% | | | | | | | |
| of tangible assets | 161.7 | 167.2 | 328.9 | 181.6 | 510.4 | 208.0 | 389.6 | 718.5 | 189.3 | | | | | | | | 17.1% | | | | | | | |
| of intangible assets | 312.3 | 288.3 | 600.6 | 282.7 | 883.3 | 344.6 | 627.3 | 1,227.9 | 242.3 | | | | | | | | -22.4% | | | | | | | |
| of financial assets | 0.0 | -2.4 | -2.4 | -0.1 | -2.5 | -0.3 | -0.3 | -2.7 | -0.1 | | | | | | | | n.m. | | | | | | | |
| Changes in working capital | -178.2 | -58.3 | -236.4 | -93.9 | -330.3 | 160.8 | 66.9 | -169.5 | -355.8 | | | | | | | | 99.7% | | | | | | | |
| Changes in inventories | -145.7 | -113.2 | -258.9 | -57.4 | -316.4 | -7.1 | -64.6 | -323.5 | -128.7 | | | | | | | | -11.7% | | | | | | | |
| Changes in trade accounts receivable | -14.9 | -103.9 | -118.8 | -23.1 | -141.9 | 95.2 | 72.1 | -46.8 | -254.3 | | | | | | | | >1.000% | | | | | | | |
| Changes in trade accounts payable | -17.5 | 158.8 | 141.3 | -13.3 | 128.0 | 72.8 | 59.5 | 200.8 | 27.1 | | | | | | | | n.m. | | | | | | | |
| Changes in provisions | 100.2 | -46.6 | 53.6 | 80.6 | 134.2 | 19.0 | 99.6 | 153.2 | 15.8 | | | | | | | | -84.2% | | | | | | | |
| Changes in other assets and liabilities | -89.1 | -25.8 | -114.9 | 128.8 | 13.9 | -404.6 | -275.8 | -390.7 | -22.9 | | | | | | | | -74.3% | | | | | | | |
| Neutralization of gain/loss on disposal of assets | 1.0 | -50.3 | -49.3 | 10.0 | -39.3 | -17.9 | -8.0 | -57.3 | -34.6 | | | | | | | | n.m. | | | | | | | |
| Other non-cash income and expenses | -5.0 | -0.2 | -5.3 | -1.0 | -6.3 | 59.5 | 58.5 | 53.2 | 24.4 | | | | | | | | n.m. | | | | | | | |
| **Net cash flows from operating activities** | **492.5** | **742.6** | **1,235.1** | **930.6** | **2,165.8** | **690.4** | **1,621.0** | **2,856.2** | **516.5** | | | | | | | | **4.9%** | | | | | | | |
| thereof: from discontinued operations | 0.0 | -11.6 | -11.6 | 11.6 | 0.0 | 0.0 | 11.6 | 0.0 | 0.0 | | | | | | | | **n.m.** | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Purchase of intangible assets | -9.2 | -83.4 | -92.6 | -29.3 | -121.8 | -86.4 | -115.6 | -208.2 | -17.9 | | | | | | | | 95.0% | | | | | | | |
| Disposal of intangible assets | 17.2 | -0.3 | 16.9 | 7.6 | 24.5 | -1.6 | 6.0 | 22.9 | 6.0 | | | | | | | | -64.9% | | | | | | | |
| Purchase of property, plant and equipment | -208.7 | -165.0 | -373.8 | -192.7 | -566.5 | -246.4 | -439.1 | -812.9 | -340.8 | | | | | | | | 63.3% | | | | | | | |
| Disposal of property, plant and equipment | 2.9 | 3.5 | 6.4 | -1.1 | 5.3 | 25.4 | 24.3 | 30.7 | 3.5 | | | | | | | | 20.0% | | | | | | | |
| Acquisitions | -0.5 | -9.7 | -10.2 | -56.4 | -66.6 | -4,960.1 | -5,009.1 | -5,019.8 | -0.8 | | | | | | | | 50.2% | | | | | | | |
| Divestments | -1.4 | -90.6 | -92.1 | -5.7 | -97.8 | -12.4 | -18.2 | -110.2 | 56.1 | | | | | | | | n.m. | | | | | | | |
| Changes/ Purchase of financial assets | -37.0 | -127.4 | -164.4 | -4.0 | -168.5 | -21.0 | -32.4 | -196.3 | -25.6 | | | | | | | | -30.8% | | | | | | | |
| Disposal of financial assets | 7.7 | 2.8 | 10.4 | 72.4 | 82.8 | 56.7 | 129.0 | 139.5 | 31.3 | | | | | | | | 309.2% | | | | | | | |
| Payments for investments in non-financial assets | -100.0 | -399.9 | -499.9 | 0.0 | -499.9 | 0.0 | 0.0 | -499.9 | 0.0 | | | | | | | | -100.0% | | | | | | | |
| Disposal of non-financial non-operative assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 501.5 | 501.5 | 501.5 | 0.0 | | | | | | | | n.m. | | | | | | | |
| **Net cash flows from investing activities** | **-329.1** | **-870.1** | **-1,199.2** | **-209.2** | **-1,408.4** | **-4,744.4** | **-4,953.6** | **-6,152.8** | **-288.1** | | | | | | | | **-12.4%** | | | | | | | |
| thereof: from discontinued operations | -4.8 | -106.9 | -111.7 | -6.4 | -118.1 | -11.3 | -17.7 | -129.4 | 0.0 | | | | | | | | **-100.0%** | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Dividend payments to Merck KGaA shareholders | 0.0 | -161.6 | -161.6 | 0.0 | -161.6 | 0.0 | 0.0 | -161.6 | 0.0 | | | | | | | | n.m. | | | | | | | |
| Dividend payments to non-controlling interests | 0.0 | -11.4 | -11.4 | -0.2 | -11.5 | -0.1 | -0.3 | -11.7 | -5.1 | | | | | | | | n.m. | | | | | | | |
| Profit transferred to E.Merck | -61.5 | -453.9 | -515.4 | 0.0 | -515.4 | 0.0 | 0.0 | -515.4 | -57.6 | | | | | | | | -6.3% | | | | | | | |
| Changes in financial liabilities to E.Merck | 9.0 | 396.7 | 405.7 | -193.8 | 212.0 | -224.4 | -418.2 | -12.4 | -34.1 | | | | | | | | n.m. | | | | | | | |
| Other changes in net equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | n.m. | | | | | | | |
| Changes in current and non-current financial liabilities | 49.2 | 1,473.8 | 1,523.1 | 1,128.0 | 2,651.1 | -48.2 | 1,079.8 | 2,602.9 | 638.2 | | | | | | | | >1.000% | | | | | | | |
| Other changes from financing activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | | | | | | | | n.m. | | | | | | | |
| **Net cash flows from financing activities** | **-3.2** | **1,243.8** | **1,240.5** | **934.1** | **2,174.7** | **-272.7** | **661.4** | **1,901.9** | **541.5** | | | | | | | | **n.m.** | | | | | | | |
| thereof: from discontinued operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | **n.m.** | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| **Changes in cash and cash equivalents** | **160.2** | **1,116.3** | **1,276.5** | **1,655.5** | **2,932.0** | **-4,326.7** | **-2,671.2** | **-1,394.7** | **769.9** | | | | | | | | **380.6%** | | | | | | | |
| Changes in cash and cash equivalents due to currency translation | 9.4 | -5.7 | 3.7 | 5.4 | 9.2 | -4.1 | 1.3 | 5.0 | -20.1 | | | | | | | | n.m. | | | | | | | |
| Cash and cash equivalents as of January 1st | 2,170.3 | 0.0 | 2,170.3 | 0.0 | 2,170.3 | 0.0 | 0.0 | 2,170.3 | 780.6 | | | | | | | | -64.0% | | | | | | | |
| **Cash and cash equivalents** | **2,340.0** | **1,110.5** | **3,450.5** | **1,661.0** | **5,111.5** | **-4,330.9** | **-2,669.9** | **780.6** | **1,530.4** | | | | | | | | **-34.6%** | | | | | | | |
| Changes in cash and cash equivalents due to change in scope of consolidation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | n.m. | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| **Business Free Cash Flow** | | | | | | | | | | | | | | | | | | | | | | | | |
| **EBITDA pre** | **928.5** | **1,139.3** | **2,067.8** | **1,111.3** | **3,179.1** | **1,205.7** | **2,316.9** | **4,384.8** | **1,181.3** | | | | | | | | **27.2%** | | | | | | | |
| CAPEX on PPE and Software | -125.7 | -193.2 | -318.9 | -209.6 | -528.5 | -497.9 | -707.5 | -1,026.4 | -175.3 | | | | | | | | 39.4% | | | | | | | |
| Changes in inventory | -172.9 | -95.9 | -268.8 | -101.9 | -370.6 | -206.9 | -308.7 | -577.5 | -101.3 | | | | | | | | -41.4% | | | | | | | |
| Changes in trade accounts receivable | -58.9 | -116.1 | -175.0 | -33.6 | -208.6 | -50.8 | -84.4 | -259.4 | -161.5 | | | | | | | | 174.3% | | | | | | | |
| Leasing payments | -26.0 | -33.1 | -59.2 | -34.8 | -94.0 | -41.8 | -76.7 | -135.8 | -36.4 | | | | | | | | 39.8% | | | | | | | |
| Adjustments Business Free Cash Flow | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 345.6 | 345.6 | 345.6 | -45.3 | | | | | | | | n.m. | | | | | | | |
| **Business Free Cash Flow** | **545.0** | **701.0** | **1,246.0** | **731.4** | **1,977.5** | **753.8** | **1,485.3** | **2,731.3** | **661.5** | | | | | | | | **21.4%** | | | | | | | |
| Healthcare | 222.1 | 345.8 | 567.8 | 310.7 | 878.5 | 373.4 | 684.0 | 1,251.8 | 377.2 | | | | | | | | 69.9% | | | | | | | |
| Life Science | 268.2 | 323.2 | 591.4 | 410.1 | 1,001.5 | 372.7 | 782.8 | 1,374.2 | 246.1 | | | | | | | | -8.2% | | | | | | | |
| Performance Materials | 172.4 | 153.2 | 325.6 | 120.7 | 446.3 | 195.1 | 315.8 | 641.4 | 184.4 | | | | | | | | 7.0% | | | | | | | |
| Corporate & Others | -117.6 | -121.2 | -238.8 | -110.0 | -348.8 | -187.3 | -297.3 | -536.1 | -146.2 | | | | | | | | 24.3% | | | | | | | |

**Balance Sheet Merck KGaA, Darmstadt, Germany**

| **Group** | **2019** | | | | **2020** | | | | **Shares of Totals** | | | | **Shares of Totals** | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| € million | 31.mar | 30.cze | 30.wrz | 31. Dez | 31.mar | 30.cze | 30.wrz | 31.gru | 31.mar | 30.cze | 30.wrz | 31. Dez | 31.mar | 30.cze | 30.wrz | 31.gru |
| **Current assets** | **10,512.5** | **11,693.9** | **13,517.6** | **9,003.3** | **10,012.8** | | | | 27.2% | 29.6% | 32.1% | 20.6% | 22.4% | | | |
| Cash and cash equivalents | 2,339.6 | 3,450.5 | 5,111.5 | 780.6 | 1,530.4 | | | | 6.0% | 8.7% | 12.2% | 1.8% | 3.4% | | | |
| Other current financial assets | 64.5 | 153.7 | 275.5 | 57.1 | 81.0 | | | | 0.2% | 0.4% | 0.7% | 0.1% | 0.2% | | | |
| Trade and other current receivables | 3,616.1 | 3,467.8 | 3,439.9 | 3,487.6 | 3,689.8 | | | | 9.3% | 8.8% | 8.2% | 8.0% | 8.2% | | | |
| Inventories | 2,937.2 | 3,033.1 | 3,134.9 | 3,341.8 | 3,443.1 | | | | 7.6% | 7.7% | 7.5% | 7.6% | 7.7% | | | |
| Contract assets | 42.4 | 71.6 | 68.5 | 156.1 | 84.7 | | | | 0.1% | 0.2% | 0.2% | 0.4% | 0.2% | | | |
| Other current non-financial assets | 1,083.9 | 1,212.8 | 1,162.5 | 591.1 | 552.9 | | | | 2.8% | 3.1% | 2.8% | 1.3% | 1.2% | | | |
| Income tax receivables | 428.9 | 304.5 | 324.7 | 589.1 | 630.9 | | | | 1.1% | 0.8% | 0.8% | 1.3% | 1.4% | | | |
| Assets held for sale | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | | |
| **Non-current assets** | **28,204.4** | **27,874.0** | **28,549.9** | **34,807.7** | **34,730.4** | | | | 72.8% | 70.4% | 67.9% | 79.4% | 77.6% | | | |
| Goodwill | 13,966.1 | 13,840.8 | 14,309.4 | 17,141.4 | 17,375.9 | | | | 36.1% | 35.0% | 34.0% | 39.1% | 38.8% | | | |
| Intangible assets other than goodwill | 7,051.6 | 6,769.8 | 6,730.4 | 9,174.6 | 9,089.3 | | | | 18.2% | 17.1% | 16.0% | 20.9% | 20.3% | | | |
| Property, plant and equipment | 5,290.8 | 5,250.7 | 5,376.3 | 6,213.3 | 6,110.4 | | | | 13.7% | 13.3% | 12.8% | 14.2% | 13.7% | | | |
| Investments at equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | | |
| Other non-current financial assets | 595.1 | 656.7 | 641.1 | 738.3 | 692.0 | | | | 1.5% | 1.7% | 1.5% | 1.7% | 1.5% | | | |
| Other non-current receivables | 14.1 | 13.3 | 14.3 | 22.3 | 21.4 | | | | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | | | |
| Other non-current non-financial assets | 81.4 | 87.8 | 89.4 | 96.6 | 93.7 | | | | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | | | |
| Deferred tax assets | 1,205.3 | 1,254.9 | 1,389.0 | 1,421.2 | 1,347.6 | | | | 3.1% | 3.2% | 3.3% | 3.2% | 3.0% | | | |
| **Total assets** | **38,716.8** | **39,567.9** | **42,067.4** | **43,811.0** | **44,743.2** | | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | |
| **Current liabilities** | **11,194.4** | **10,494.3** | **9,655.1** | **11,841.6** | **10,764.3** | | | | 28.9% | 26.5% | 23.0% | 27.0% | 24.1% | | | |
| Current financial debt | 4,442.8 | 4,932.9 | 3,930.3 | 4,550.4 | 3,716.7 | | | | 11.5% | 12.5% | 9.3% | 10.4% | 8.3% | | | |
| Trade and other current payables | 1,632.8 | 1,737.0 | 1,736.3 | 2,053.8 | 1,807.4 | | | | 4.2% | 4.4% | 4.1% | 4.7% | 4.0% | | | |
| Refund liabilities | 541.3 | 564.8 | 587.4 | 564.6 | 626.1 | | | | 1.4% | 1.4% | 1.4% | 1.3% | 1.4% | | | |
| Other current financial liabilities | 1,384.6 | 543.2 | 629.9 | 1,126.5 | 1,021.4 | | | | 3.6% | 1.4% | 1.5% | 2.6% | 2.3% | | | |
| Other current non-financial liabilities | 1,322.9 | 1,064.8 | 1,099.5 | 1,211.2 | 1,225.5 | | | | 3.4% | 2.7% | 2.6% | 2.8% | 2.7% | | | |
| Income tax liabilities | 1,279.4 | 1,106.7 | 1,126.4 | 1,401.9 | 1,463.0 | | | | 3.3% | 2.8% | 2.7% | 3.2% | 3.3% | | | |
| Current provisions | 494.3 | 482.8 | 451.8 | 823.3 | 822.0 | | | | 1.3% | 1.2% | 1.1% | 1.9% | 1.8% | | | |
| Current employee benefit provisions | 96.2 | 62.1 | 93.4 | 109.9 | 82.1 | | | | 0.2% | 0.2% | 0.2% | 0.3% | 0.2% | | | |
| Liabilities included in disposal groups classified as held for sale | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | | |
| **Non-current liabilities** | **9,846.7** | **11,499.4** | **14,230.1** | **14,055.6** | **15,378.6** | | | | 25.4% | 29.1% | 33.8% | 32.1% | 34.4% | | | |
| Non-current financial debt | 5,047.2 | 6,497.2 | 8,614.2 | 8,643.8 | 10,136.6 | | | | 13.0% | 16.4% | 20.5% | 19.7% | 22.7% | | | |
| Other non-current financial liabilities | 36.5 | 34.2 | 32.8 | 43.4 | 44.1 | | | | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | | | |
| Other non-current non-financial liabilities | 225.7 | 225.6 | 225.4 | 93.2 | 90.1 | | | | 0.6% | 0.6% | 0.5% | 0.2% | 0.2% | | | |
| Non-current provisions | 630.1 | 632.4 | 656.4 | 253.7 | 252.3 | | | | 1.6% | 1.6% | 1.6% | 0.6% | 0.6% | | | |
| Non-current employee benefit provisions | 2,688.8 | 2,947.4 | 3,518.1 | 3,193.5 | 3,060.5 | | | | 6.9% | 7.4% | 8.4% | 7.3% | 6.8% | | | |
| Deferred tax liabilities | 1,218.3 | 1,162.5 | 1,183.2 | 1,828.0 | 1,795.1 | | | | 3.1% | 2.9% | 2.8% | 4.2% | 4.0% | | | |
| **Net equity** | **17,675.8** | **17,574.3** | **18,182.3** | **17,913.8** | **18,600.2** | | | | 45.7% | 44.4% | 43.2% | 40.9% | 41.6% | | | |
| Equity capital | 565.2 | 565.2 | 565.2 | 565.2 | 565.2 | | | | 1.5% | 1.4% | 1.3% | 1.3% | 1.3% | | | |
| Capital reserves | 3,813.7 | 3,813.7 | 3,813.7 | 3,813.7 | 3,813.7 | | | | 9.9% | 9.6% | 9.1% | 8.7% | 8.5% | | | |
| Retained earnings | 11,294.2 | 11,410.2 | 12,018.5 | 11,507.0 | 11,977.5 | | | | 29.2% | 28.8% | 28.6% | 26.3% | 26.8% | | | |
| Gain/losses recognized immediately in equity | 1,967.3 | 1,761.0 | 1,761.0 | 1,979.6 | 2,199.9 | | | | 5.1% | 4.5% | 4.2% | 4.5% | 4.9% | | | |
| Non-controlling interest | 35.4 | 24.1 | 23.8 | 48.3 | 43.9 | | | | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | | | |
| **Total liabilities and stockholders' equity** | **38,716.8** | **39,567.9** | **42,067.4** | **43,811.0** | **44,743.2** | | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | |

| | **2018** | | | | **2019** | | | | **Shares of Totals** | | | | **Shares of Totals** | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 31.mar | 30.cze | 30.wrz | 31. Dez | 31.mar | 30.cze | 30.wrz | 31.gru | 31.mar | 30.cze | 30.wrz | 31. Dez | 31.mar | 30.cze | 30.wrz | 31.gru |
| Financial debt | 9,490.0 | 11,430.1 | 12,544.5 | 13,194.2 | 13,853.3 | | | | 24.5% | 28.9% | 29.8% | 30.1% | 31.0% | | | |
| Net financial debt | 7,089.4 | 7,829.4 | 7,320.0 | 12,363.2 | 12,284.6 | | | | 18.3% | 19.8% | 17.4% | 28.2% | 27.5% | | | |

**Income Statement Merck KGaA, Darmstadt, Germany**

| **Group**<br>€ million | 2019 | | | | | | | | 2020 | | | | | | | | Change YoY | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| **Financial result** | -112.6 | -61.1 | -173.7 | -134.9 | -308.5 | -76.1 | -210.9 | -384.6 | -98.5 | | | | | | | | -12.5% | | | | | | | |
| **Interest result** | -57.6 | -55.5 | -113.0 | -85.4 | -198.5 | -93.8 | -179.2 | -292.3 | -80.0 | | | | | | | | 39.0% | | | | | | | |
| Interest income | 6.7 | 22.0 | 28.6 | 6.9 | 35.6 | 30.1 | 37.1 | 65.7 | 5.6 | | | | | | | | -15.2% | | | | | | | |
| Interest expenses | -64.2 | -77.5 | -141.7 | -92.4 | -234.1 | -123.9 | -216.3 | -358.0 | -85.7 | | | | | | | | 33.4% | | | | | | | |
| **Result from financial investments** | -0.4 | -0.5 | -0.9 | 0.2 | -0.6 | 0.5 | 0.7 | -0.1 | -0.1 | | | | | | | | -66.8% | | | | | | | |
| **Currency difference - financing** | -37.7 | 2.3 | -35.4 | 3.1 | -32.3 | -0.7 | 2.5 | -33.0 | -6.0 | | | | | | | | -84.0% | | | | | | | |
| **Interest quota - pensions and other provi** | -17.0 | -6.8 | -23.8 | -52.8 | -76.6 | 18.0 | -34.8 | -58.6 | -12.3 | | | | | | | | -27.5% | | | | | | | |
| **Others** | 0.0 | -0.6 | -0.6 | 0.0 | -0.6 | 0.0 | 0.0 | -0.6 | 0.0 | | | | | | | | n.m. | | | | | | | |